Goldline Pharmaceutical Ltd

Goldline Pharmaceutical Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Goldline Pharmaceutical Ltd

₹ 43.0 -0.28%
10 Jun 9:32 a.m.
Company website BSE - SME: 544759
About

Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.”[1]

Key Points

Business Profile:[1]
Goldline Pharmaceutical is engaged in the marketing and distribution of pharmaceutical products under the “Goldline” brand through
an asset-light, third-party manufacturing model. The company does not manufacture products
in-house; instead, it partners with contract manufacturers for production while focusing
on product selection, branding, distribution, marketing, and supply chain management.

Website BSE
  • Market Cap ₹ 41.3 Cr.
  • Current Price ₹ 43.0
  • High / Low ₹ 60.0 / 41.8
  • Stock P/E 14.2
  • Book Value ₹
  • Dividend Yield 0.00 %
  • ROCE 29.2 %
  • ROE 39.7 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 31.2%

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE SME IPO

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Operating Profit
OPM %
Interest
Depreciation
Profit before tax
Tax %
EPS in Rs
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2023 Mar 2024 Mar 2025
19.73 23.48 28.01
17.32 19.14 21.86
Operating Profit 2.41 4.34 6.15
OPM % 12.21% 18.48% 21.96%
-0.20 -0.04 -0.09
Interest 1.63 1.61 1.95
Depreciation 0.18 0.16 0.25
Profit before tax 0.40 2.53 3.86
Tax % 37.50% 28.46% 26.42%
0.26 1.81 2.83
EPS in Rs 1.30 7.87 4.10
Dividend Payout % 0.00% 0.00% 0.00%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 19%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 58%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 31%
Last Year: 40%

Balance Sheet

Figures in Rs. Crores

Mar 2023 Mar 2024 Mar 2025
Equity Capital 2.00 2.30 6.90
Reserves 2.08 3.76 1.65
12.64 12.94 12.85
2.67 3.93 4.88
Total Liabilities 19.39 22.93 26.28
2.50 2.95 2.89
CWIP 0.00 0.45 0.00
Investments 0.07 0.03 0.04
16.82 19.50 23.35
Total Assets 19.39 22.93 26.28

Cash Flows

Figures in Rs. Crores

Mar 2023 Mar 2024 Mar 2025
2.39 2.92 2.32
-1.04 -1.11 0.16
-1.44 -1.08 -2.03
Net Cash Flow -0.09 0.74 0.45
Free Cash Flow 1.38 1.81 2.49
CFO/OP 101% 72% 53%

Ratios

Figures in Rs. Crores

Mar 2023 Mar 2024 Mar 2025
Debtor Days 159.65 149.54 139.30
Inventory Days 336.20 450.39 229.14
Days Payable 54.47 98.62 69.62
Cash Conversion Cycle 441.39 501.32 298.82
Working Capital Days 143.74 132.76 134.74
ROCE % 23.40% 29.21%

Shareholding Pattern

Numbers in percentages

16 Recently
May 2026
57.29%
5.16%
7.81%
29.74%
No. of Shareholders 271

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

No data available.

Credit ratings